Mosley Wealth Management Invests $333,000 in Merck & Co., Inc. (NYSE:MRK)

Mosley Wealth Management purchased a new position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 3,058 shares of the company’s stock, valued at approximately $333,000.

Several other institutional investors and hedge funds also recently made changes to their positions in MRK. Vermillion & White Wealth Management Group LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $27,000. Bare Financial Services Inc purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $28,000. Burkett Financial Services LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $28,000. Rakuten Securities Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $30,000. Finally, RIA Advisory Group LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $30,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $130.67 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The stock has a 50 day moving average price of $128.51 and a two-hundred day moving average price of $121.61. The company has a market capitalization of $330.96 billion, a P/E ratio of 145.19, a PEG ratio of 2.52 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the previous year, the firm earned $1.40 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be paid a dividend of $0.77 per share. The ex-dividend date is Monday, June 17th. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on MRK shares. Societe Generale downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a research report on Monday, March 11th. Berenberg Bank boosted their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Finally, TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $133.00.

Read Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.